## 1,1-Bis(4-hydroxyphenyl)ethane: A Versatile Building Block
1,1-Bis(4-hydroxyphenyl)ethane, also known as **bisphenol A (BPA)**, is a **synthetic organic compound** with the chemical formula C₁₅H₁₆O₂. Its structure consists of two phenol rings connected to a central ethane bridge.
BPA's importance stems from its **versatility** as a **monomer** in the production of various **polymers** used in numerous applications:
**1. Polycarbonate Plastics:** BPA is the primary monomer for producing polycarbonate, a strong, clear, and impact-resistant thermoplastic. Polycarbonate is used in numerous consumer products like:
* **Food and beverage containers**
* **CDs and DVDs**
* **Eyeglasses**
* **Medical devices**
* **Automotive parts**
**2. Epoxy Resins:** BPA is also used as a building block for epoxy resins, commonly used in:
* **Coatings and adhesives**
* **Construction materials**
* **Electronics**
**3. Other Applications:**
* **Polyurethane foams**
* **Printing inks**
* **Flame retardants**
**Importance in Research:**
**a) Endocrine Disruptor:**
* **BPA has been identified as an endocrine disruptor.** This means it can interfere with the body's hormonal system, potentially leading to various health concerns, including reproductive problems, metabolic disorders, and increased risk of certain cancers.
* Extensive research investigates the **mechanisms of BPA's endocrine disruption, its impact on human health, and potential alternatives to BPA.**
**b) Environmental Concerns:**
* **BPA's widespread use and potential environmental release raise concerns about its impact on ecosystems and wildlife.**
* Research explores **BPA's fate in the environment, its persistence, and its potential bioaccumulation in organisms.**
**c) Material Science:**
* **BPA's unique properties make it a valuable component in various materials.**
* Research focuses on developing **new, improved, and sustainable alternatives to BPA** to address its potential health and environmental risks.
**d) Medical Applications:**
* Some research investigates potential **therapeutic applications of BPA derivatives** for conditions like cancer and Alzheimer's disease.
**Overall, 1,1-Bis(4-hydroxyphenyl)ethane remains a subject of significant research due to its widespread use, potential health and environmental concerns, and ongoing efforts to find suitable alternatives.**
ID Source | ID |
---|---|
PubMed CID | 608116 |
CHEMBL ID | 2392656 |
CHEBI ID | 34029 |
SCHEMBL ID | 26946 |
Synonym |
---|
AKOS015838553 |
1,1-bis(4-hydroxyphenyl)ethane |
bisphenol e |
4,4'-ethylidenebisphenol, 99% |
hcnhnblsnvsjtj-uhfffaoysa- |
inchi=1/c14h14o2/c1-10(11-2-6-13(15)7-3-11)12-4-8-14(16)9-5-12/h2-10,15-16h,1h3 |
4,4'-ethylidenediphenol |
E0432 |
2081-08-5 |
4,4'-ethylidenebisphenol |
4-[1-(4-hydroxyphenyl)ethyl]phenol |
NCGC00248698-01 |
dtxcid9027867 |
tox21_200555 |
NCGC00258109-01 |
dtxsid3047891 , |
cas-2081-08-5 |
CHEMBL2392656 , |
chebi:34029 , |
4,4'-ethane-1,1-diyldiphenol |
STL371128 |
SCHEMBL26946 |
1,1-bis(4-hydroxyphenyl) ethane |
4,4'-(ethane-1,1-diyl)diphenol |
tox21_304007 |
NCGC00357018-01 |
phenol, 4,4'-ethylidenebis- |
J-514031 |
bisphenol e, analytical standard |
AS-59101 |
phenol, 4,4'-ethylidenedi- (6ci,7ci,8ci); 4,4'-ethylidenebis[phenol]; 1,1-bis(4-hydroxyphenyl)ethane; 4,4'-ethylidenediphenol; bisphenol ad; bisphenol e |
H48 , |
Q15726108 |
D80927 |
EN300-248172 |
bdbm50544708 |
CS-0154101 |
bisphenol e 100 microg/ml in methanol |
Excerpt | Reference | Relevance |
---|---|---|
" Nevertheless, only few studies have reported on the toxic effect of bisphenol analogues on phytoplankton." | ( Toxic effects of bisphenol A and its analogues on cyanobacteria Anabaena variabilis and Microcystis aeruginosa. Czarny, K; Krawczyk, B; Szczukocki, D, 2021) | 0.62 |
Class | Description |
---|---|
diarylmethane | Any compound containing two aryl groups connected by a single C atom. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Luciferase | Photinus pyralis (common eastern firefly) | Potency | 59.7250 | 0.0072 | 15.7588 | 89.3584 | AID1224835 |
RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 43.4384 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
GLI family zinc finger 3 | Homo sapiens (human) | Potency | 21.6530 | 0.0007 | 14.5928 | 83.7951 | AID1259369; AID1259392 |
AR protein | Homo sapiens (human) | Potency | 24.4713 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247; AID743035; AID743063 |
estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 13.8554 | 0.0006 | 57.9133 | 22,387.1992 | AID1259377; AID1259378; AID1259394 |
nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 40.0666 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224839; AID1224893 |
progesterone receptor | Homo sapiens (human) | Potency | 29.4586 | 0.0004 | 17.9460 | 75.1148 | AID1346784; AID1346795 |
retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 24.9528 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159553; AID1159555 |
estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 54.1010 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224848; AID1224849 |
pregnane X nuclear receptor | Homo sapiens (human) | Potency | 53.3215 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 22.9562 | 0.0002 | 29.3054 | 16,493.5996 | AID1259383; AID743069; AID743075; AID743077; AID743078; AID743079 |
peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 40.9113 | 0.0010 | 24.5048 | 61.6448 | AID743215 |
peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 36.4622 | 0.0010 | 19.4141 | 70.9645 | AID743191 |
aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 25.5935 | 0.0007 | 23.0674 | 1,258.9301 | AID743085 |
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 18.1188 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 54.4827 | 0.0016 | 28.0151 | 77.1139 | AID1224895 |
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 0.0029 | 19.7391 | 45.9784 | 64.9432 | AID1159509 |
Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 56.6363 | 0.0391 | 47.5451 | 146.8240 | AID1224845; AID1224896 |
thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 28.7164 | 0.0003 | 23.4451 | 159.6830 | AID743065 |
nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 27.7167 | 0.0006 | 27.2152 | 1,122.0200 | AID743202; AID743219 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Estrogen receptor | Homo sapiens (human) | IC50 (µMol) | 6.1600 | 0.0000 | 0.7237 | 32.7000 | AID1666467 |
Estrogen receptor beta | Homo sapiens (human) | IC50 (µMol) | 2.4000 | 0.0001 | 0.5294 | 32.7000 | AID1666468 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Estrogen receptor | Homo sapiens (human) | EC50 (µMol) | 10.0000 | 0.0000 | 0.5305 | 4.4000 | AID1666470 |
Estrogen receptor beta | Homo sapiens (human) | EC50 (µMol) | 1.3950 | 0.0000 | 0.4795 | 4.8900 | AID1666471 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1666472 | Antagonist activity at ERbeta (unknown origin) expressed in human HeLa cells assessed as inhibition of E2-induced transcriptional activity measured after 24 hrs by luciferase reporter gene assay based Schild plot analysis | |||
AID1666468 | Displacement of [3H]17-beta estradiol from GST-fused human recombinant ERbeta ligand binding domain expressed in Escherichia coli BL21alpha cells incubated for 1 hr by liquid scintillation counting method | |||
AID1666470 | Agonist activity at ERalpha (unknown origin) expressed in human HeLa cells assessed as transcriptional activation measured after 24 hrs by luciferase reporter gene assay | |||
AID1666471 | Agonist activity at ERbeta (unknown origin) expressed in human HeLa cells assessed as transcriptional activation measured after 24 hrs by luciferase reporter gene assay | |||
AID752867 | Inhibition of rabbit skeletal muscle sarco/endoplasmic reticulum calcium ATPase assessed as inhibition of ATP hydrolysis by spectrophotometric analysis | 2013 | Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13 | Structural requirements for inhibitory effects of bisphenols on the activity of the sarco/endoplasmic reticulum calcium ATPase. |
AID1666467 | Displacement of [3H]17-beta estradiol from GST-fused human recombinant ERalpha ligand binding domain expressed in Escherichia coli BL21alpha cells incubated for 1 hr by liquid scintillation counting method | |||
AID1666469 | Selectivity index, ratio of IC50 for GST-fused human recombinant ERalpha ligand binding domain expressed in Escherichia coli BL21alpha cells to IC50 for GST-fused human recombinant ERbeta ligand binding domain expressed in Escherichia coli BL21alpha cells | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 4 (25.00) | 24.3611 |
2020's | 12 (75.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.19) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 16 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |